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Abstract
Introduction: The English Department of Health introduced universal MRSA screening of admissions to English
hospitals in 2010. It commissioned a national audit to review implementation, impact on patient management,
admission prevalence and extra yield of MRSA identified compared to “high-risk” specialty or “checklist-activated”
screening (CLAS) of patients with MRSA risk factors.
Methods: National audit May 2011. Questionnaires to infection control teams in all English NHS acute trusts,
requesting number patients admitted and screened, new or previously known MRSA; MRSA point prevalence;
screening and isolation policies; individual risk factors and patient management for all new MRSA patients and
random sample of negatives.
Results: 144/167 (86.2%) trusts responded. Individual patient data for 760 new MRSA patients and 951 negatives.
61% of emergency admissions (median 67.3%), 81% (median 59.4%) electives and 47% (median 41.4%) day-cases
were screened. MRSA admission prevalence: 1% (median 0.9%) emergencies, 0.6% (median 0.4%) electives, 0.4%
(median 0%) day-cases. Approximately 50% all MRSA identified was new. Inpatient MRSA point prevalence: 3.3%
(median 2.9%). 104 (77%) trusts pre-emptively isolated patients with previous MRSA, 63 (35%) pre-emptively
isolated admissions to “high-risk” specialties; 7 (5%) used PCR routinely. Mean time to MRSA positive result: 2.87
days (±1.33); 37% (219/596) newly identified MRSA patients discharged before result available; 55% remainder
(205/376) isolated post-result. In an average trust, CLAS would reduce screening by 50%, identifying 81% of all
MRSA. “High risk” specialty screening would reduce screening by 89%, identifying 9% of MRSA.
Conclusions: Implementation of universal screening was poor. Admission prevalence (new cases) was low. CLAS
reduced screening effort for minor decreases in identification, but implementation may prove difficult. Cost
effectiveness of this and other policies, awaits evaluation by transmission dynamic economic modelling, using data
from this audit. Until then trusts should seek to improve implementation of current policy and use of isolation facilities.
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Introduction
Due to the historically high prevalence, mortality and cost of
healthcare associated meticillin resistant Staphylococcus
aureus (MRSA) infection [1,2], legislation [3] and many national
infection control interventions [4-6] were introduced in the
English National Health Service (NHS). Several of these
interventions were associated with subsequent reductions in
MRSA [3]. Annual MRSA bacteraemia rates fell by 85%
between April 2003 and March 2011 [7]. Preventing healthcare
associated infections (HCAI) remains a national priority and the
introduction of a zero tolerance approach (and a target of zero
MRSA bacteraemias for all healthcare organisations) is a major
requirement in the NHS Operating Framework 2012-13 [8].
The basis of reduction of transmission of MRSA is hand
hygiene (6), isolation of MRSA positive patients, suppression/
decolonisation therapy and screening for asymptomatic carriers
[2,9,10]. United Kingdom (U.K.) national guidance in 2006,
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recommended “targeted screening” of individual patients in
“high-risk” specialties (defined as Nephrology, Neurosurgery,
Orthopaedics and Trauma, Haematology and Oncology,
Vascular Surgery and Cardiothoracic Surgery) where infections
were likely to be deep-seated and hard to treat [2] and/or
screening of patients with known risk factors for MRSA
carriage. Hospitals had discretion to implement these
guidelines according to local circumstances.
The English Department of Health introduced universal
mandatory MRSA screening of all elective admissions, except
for paediatric, maternity and some day-cases (ophthalmology,
endoscopy, minor dermatology) from April 2009 and of all
emergency admissions to acute NHS hospitals from December
2010, on the basis of an impact assessment model of the cost-
effectiveness of different screening and decolonisation
strategies [11]. It is unclear, however, from the limited clinical
studies performed in the UK [12-16] or from modelling studies
[10,17-19] which of these two screening strategies (“targeted
screening of admissions to high-risk specialties” or “universal”)
is more clinically or cost-effective, or how they compare with
checklist activated screening (i.e. assessing all admissions with
a checklist of clinical risk factors for MRSA carriage and
screening those with at least one risk factor). One modelling
study reported little difference between long term prevalence
levels achieved by these strategies but found that targeted and
checklist activated screening were associated with substantial
savings [19].
As the Department of Health’s impact assessment and other
mathematical models of the effectiveness and cost-
effectiveness of universal mandatory screening were not
populated by representative data from NHS hospitals
[10,17-19] the Department was committed to reviewing the
effectiveness of the new policy. The National Audit Office [20]
and the Parliamentary Accounts Committee [21] also called for
a robust review of the implementation of the policy, its
effectiveness and cost-effectiveness, and its impact on patients
and their management. The English Department of Health,
therefore, commissioned a national audit of MRSA screening
with the following aims:
1 To report on current implementation of the policy of universal
screening of all emergency and elective admissions.
2 To report the prevalence rates of MRSA carriage on
admission in emergency and elective admissions and the
proportion of carriage that was previously unknown.
3 To report on screening, swabbing, isolation and
decolonisation policies and practices and laboratory methods.
4 To report on how patients were managed: how soon results
were available, numbers of patients isolated and/or
decolonised pre-emptively or after the result was known,
numbers treated for MRSA infection.
5 To determine the extra yield of MRSA positive patients
identified by universal admission screening, compared to: (a)
Screening only admissions to “high-risk” specialties (b)
“Checklist activated screening” of all admissions (c) Screening
all admissions to high-risk specialties plus checklist activated
screening for all other admissions.
Methods
Ethics Statement
The National Research Ethics Service considered the study
to be an audit and that it therefore did not require formal ethical
approval.
Study Design
A national one-week prevalence audit of MRSA screening
was carried out through a questionnaire (see File S1) sent to
infection control teams in all 167 English NHS acute trusts (a
trust being the administrative unit of a small number of acute
hospitals) at the end of April 2011, for completion in the audit
week of 9-15th May 2011.
The questionnaire was piloted in 10 trusts in early 2011 for
face-validity and feasibility of data collection with further
changes made following focus groups with representatives
from 125 hospital infection control teams in nine regional
meetings.
The questionnaire requested data on:
1 The number of elective, emergency and day-case patients
admitted and screened in the week of 11th-17th April and the
numbers admitted to the “high-risk” specialties defined as per
previous guidelines [2](nephrology, neurology, trauma &
orthopaedics, haematology & oncology, vascular surgery and
cardithoracic surgery). ITU was not included as a “high-risk”
specialty for the purposes of data collection since patients are
classified on database systems according to their admitting
specialty and not whether they were admitted to ITU.
2 The numbers of new and previously known MRSA positive
screens that week.
3 Local screening, isolation, decolonisation practices, routine
laboratory methods and costs.
4 Point-prevalence of MRSA colonised and infected patients in
each trust on Wednesday 11th May 2011 and whether they
were isolated or not.
5 Individual patient level data for all newly identified MRSA
positive patients and a random sample of 5-10 MRSA negative
patients detected on admission or at preadmission clinics
during the audit week of 9th-15th May: age, specialty (high-, or
low-risk), acute-, or elective-screen, date of screen, admission
and discharge, time to result, pre-, and post-result
management (isolation and decolonisation) and the presence
of well- recognised [12] risk factors for MRSA carriage on a six
item checklist (admission to the trust within the last year,
admission to any other trust in the last year, transfer from
another hospital, care home resident, presence of indwelling
devices/presence of skin breaks). For MRSA negative patients,
previous history of MRSA carriage was also sought.
The random sample of MRSA negative patients was
generated by consecutive numbering of all such patients that
week and using an online research randomiser tool (http://
www.randomizer.org/form.htp) to select 5-10 MRSA negative
patients. Infection control teams were asked to make all
reasonable efforts to interrogate relevant databases, review
medical and nursing notes, and, if possible, the patient, and
discuss with nursing staff to clarify uncertainties. Patients were
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regarded as checklist positive if they had at least one risk
factor. If there was no documented, clinical or database
evidence of these risk factors, it was assumed that they were
not present.
Simple descriptive statistics were used to describe the
results for all acute trusts combined and for different trust
types, which were defined according to standard definitions
used in mandatory reporting as “acute” (ie middle sized,
general hospitals providing services for local populations),
“teaching” (ie larger hospitals, providing medical training and
general services locally plus more specialised services
regionally), “specialist” (ie smaller single specialty hospitals
providing services at a regional and/or national level).
When calculating the yield of different screening strategies,
numbers were derived from questionnaire data (average
number of newly identified and previously known MRSA
positive admission screens per trust divided by the average
numbers of MRSA screens). Numbers were broken down by
trust type, specialty and admission type (emergency or
elective). Proportions of admissions that were expected to be
checklist positive were derived from the individual level patient
data collected from MRSA positive and MRSA negative
patients.
Results
Response rate
Responses were received from 144/167 (86%) trusts
(comprising 19/20 (95%) specialist trusts, 23/26 (89%) teaching
and 100/121 (83%) acute trusts). Data were also received from
two trusts that did not include their unique identifier; their data
are therefore included only when data are presented for “all
trusts”.
Data on isolation, decolonisation, screening policies and
laboratory methods were provided by 143/144 trusts.
Individual patient data on risk factors and management of
951 randomly selected patients screening negative for MRSA
in the audit week was collectively provided by 141/167 trusts
(84%) (mean [standard deviation] 6.7 [± 2.5] per trust). 131/167
(78%) trusts provided data on 760 MRSA patients newly
identified by screening that week (mean per trust 5.3 [±4.96]).
Eleven trusts (7%) reported no newly identified MRSA positive
patients in that week.
Implementation of national universal MRSA screening
policy across the NHS
Table 1 shows that for the NHS as a whole, 82% of elective,
61% of emergency and 48% of day-case admissions were
screened (median and interquartile range presented in Table
1). However, screening coverage of day-case patients in
Specialist trusts was greater, with 74% being screened.
Prevalence of MRSA carriage on admission
The overall prevalence of MRSA on admission was 1.4%
(1420/102,397) (median 1.1%, IQR 0.8%-1.9%): 2.1% for
emergency admissions, 0.9% for elective admissions and 0.7%
for day-case admissions (Table 2). The prevalence of newly
identified MRSA was approximately half of this at 0.8%
(overall): 1% (emergency), 0.6% (elective) and 0.4% (day-
cases).
The number of patients needing to be screened for
identification of one new MRSA positive patient was 102, 180
and 259 for emergency, elective and day-cases respectively
(Table 3). Screening efficiencies varied by trust type and type
of admission screened: the most efficient being screening of
electives in Specialist trusts, requiring only 84 screens for one
new MRSA positive identification, while day-cases in Acute
trusts required 462 screens to detect one new MRSA positive
patient.
Screening, isolation and decolonisation policies and
practices, and laboratory methods
Screening policies: Only 10% (14/143) of trusts (all 14 being
specialist trusts) screened all patients on admission, while the
majority exempted all or some of the following categories as
per Department of Health advice: low-risk paediatrics or
endoscopy cases, dermatology, ophthalmic and dental day-
cases.
Table 1. Mean and median (inter-quartile range) proportion
per trust of admissions screened for MRSA.
Admission
category All trusts1 Acute Trusts 2 Specialist Teaching 2
Emergency
60.6%
(52,788/87,165)
130 trusts
Median 67.3%
IQR
(47.5%-85.8%)
60%
(38,127/63,577)
91 trusts
Median 67.1%
IQR
(47.4-85.8%)
56.4%
(657/1,166)
17 trusts
Median
85.9% IQR
(68.3-100%)
62.5%
(13,736/21,988)
21 trusts
Median 59.4%
IQR
(48.9-89.2%)
Elective3
81.8%
(22,773/27,838)
115 trusts
Median 59.4%
IQR
(48.9-89.2%)
87.7%
(14,477/16,497)
77 trusts
Median 92%
IQR (59-136%)
75.4%
(1652/2,191)
16 trusts
Median 86%
IQR
(62-100%)
72.6%
(6,569/9,044)
20 trusts
Median 73%
IQR (30-102%)
Day-
cases4
47.9%
(22,416/46,777)
110 trusts
Median 41.4%
IQR
(23.2-78.9%)
43.3%
(14,255/32,927)
77 trusts
Median 36.5%
IQR
(17.4-73.9%)
73.5%
(1,153/1,568)
13 trusts
Median
67.3% IQR
(42.6-100%)
57.8%
(6,894/1,1927)
19 trusts
Median 48.3%
IQR
(36.1-77.7%)
1 Two trusts did not include their unique identifier; their data are therefore
included under “all trusts”; one of these did not return day-case data and one did
not return emergency data.
2 Median values may exceed 100% due to the numerator including pre-
admission screens from patients not admitted in that week and the denominator
including patients who were admitted but not screened in that week (i.e. screened
at a pre-admission clinic in a previous week).
3 not including day-cases
4 not including dermatology, endoscopy, ophthalmic and paediatrics
doi: 10.1371/journal.pone.0074219.t001
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Isolation and decolonisation policies: The use of pre-emptive
isolation for patients with a past history of MRSA or of patients
in locally defined high-risk specialties or categories was
reported by 77% and 44% of trusts respectively (Table 4). Pre-
emptive decolonisation of these patients was reported by 35%
and 41% of trusts respectively.
Laboratory methods: The most common technique reported
for routine processing of admission swabs was a chromogenic
agar plating for both emergencies (116 of 142 responding
trusts: 81.7%) and electives (123/141: 87.2%). PCR for routine
processing of emergency admission screens was reported in
7/142 responding trusts (5%) and in 1/141 (0.7%) for elective
admissions.
Further details of policies, decolonisation regimes and
laboratory methods are reported in the (File S2).
Patient management – point prevalence data
On the day of the point-prevalence audit 140 trusts
collectively reported that 3.3% (3,076/92,619) of all inpatients
in the hospital were known to be MRSA positive [median 2.9%,
IQR 1.8-4%]. By trust type this proportion was 3.6%
(2191/61628 patients) [median 3.6%, IQR 2.1-4.8%] for acute
trusts, for teaching trusts 3.0% (758/25146 patients) [median
3.1%, IQR 1.9-3.8%] and for specialist trusts 2% (65/3285
patients) [median 1.4%, IQR 0.9-3.4%].
In the 139 trusts reporting data on intervention measures,
67% (2,026/3,033) of MRSA patients were isolated. Of these,
91% (1,837/2,026) were in side-rooms, 4% (82/2,026) in a
designated ward and 5% (107/2,026) in a cohort bay. The
remaining third were not isolated. In specialist trusts isolation
rates were greater with 98.5% (64/65) of MRSA positive in-
patients being isolated. In addition, 127 trusts reported that
11% (286/2,680) of MRSA positive inpatients were receiving
antibiotic treatment for MRSA infection on that day [median
9.1%, IQR 0-16.7%].
Patient management – individual patient data
In addition to the point-prevalence audit, individual patient
management data were available for the group of 760 newly
identified MRSA positive patients and for the group of 951
randomly sampled patients screening negative for MRSA.
Checklists for risk factors for MRSA colonisation were
Table 3. Numbers needed to screen to identify one new
MRSA case.
 All trusts Acute Specialist Teaching
Emergency 102(50,739/498)
97
(36,083/374) 163 (652/4)
115
(13,736/119)
Elective (not
including day-
cases)
180
(19,283/107)
191
(12,953/68)
84
(1,346/16) 213 (4,909/23)
Day-cases 259(20,461/79)
462
(12,469/27)
212
(1,062/5) 145 (6,816/47)
doi: 10.1371/journal.pone.0074219.t003
Table 4. Trusts initiating precautions on admitted patients
before MRSA results available (n= 143 trusts; more than
one response possible).
 Isolation Contact precautions 1 Decolonisation
All patients 2 (1.4%) 30 (21%) 14 (10%)
All previous MRSA +ves 110 (77%) 85 (59%) 50 (35%)
High-risk patients/wards 63 (44%) 33 (23%) 59 (41%)
Other 12 (8%) 5 (3.5%) 3 (2%)
None 10 (7%) 20 (14%) 49 (34%)
1 i.e. disposable gloves and aprons
doi: 10.1371/journal.pone.0074219.t004
Table 2. Mean and median (inter-quartile range) proportion per trust of admission screens that were MRSA positive (all
MRSA positives and newly positive for MRSA).
Admission
Category
MRSA
+ves All trusts Acute Specialist Teaching
Emergency Total 2.1% (1,075/52,064 in 129 trusts)Median 1.6% IQR (1.1-2.7%)
2.2%(836/37,408 in 90 trusts) Median
2% IQR (1.2-2.7)
1% (5/652 in 16 trusts) Median
0% IQR (0-0.2%)
1.7% (230/13,736 in 22 trusts)
Median 1.7% IQR (1.1-2.4%)
 New 1% (498/50,739 in 127 trusts)Median 0.9% IQR (0.4-1.3%)
1% (374/36,083 in 88 trusts) Median
1.0% IQR (0.5-1.5%)
0.6% (4/652 in 16 trusts)
Median 0% IQR (0-0%)
0.9% (119/13,736 in 22 trusts)
Median 0.8% IQR (0.5-1.3%)
Elective1 Total 0.9% (188/20,798 in 101 trusts)Median 0.7% IQR (0-1.9%)
0.8% (110/13,532 in 68 trusts)
Median 0.7% IQR (0-2.5%)
1.7% (25/1,488 in 15 trusts)
Median 0.5% IQR (0.3-1.5%)
0.9% (53/5,703 in 17 trusts)
Median 0.6% IQR (0.5-1.1%)
 New 0.6% (107/19,283 in 98 trusts)Median 0.4% IQR (0-1.2%)
0.5% (68/12,953 in 68 trusts) Median
0.4% IQR (0-1.5%)
1.2% (16/1,346 in 14 trusts)
Median 0.5% IQR (0-1.4%)
0.5% (23/4,909 in 15 trusts)
Median 0.5% IQR (0-1.4%)
Day-case 2 Total 0.7% (150/21,501 in 112 trusts)Median 0% IQR (0-1%)
0.4% (58/13,509 in 76 trusts) Median
0% IQR (0-0.6%)
0.6% (6/1,062 in 16 trusts)
Median 0% IQR (0-1.1%)
1.2% (85/6,816 in 19 trusts)
Median 0.7% IQR (0.3-1.2%)
 New 0.4% (79/20,461 in 110 trusts)Median 0% IQR (0-0.1%)
0.2% (27/12,469 in 74 trusts) Median
0% IQR (0-0.2%)
0.5% (5/1,062 in 16 trusts)
Median 0% IQR (0-0%)
0.7% (47/6,816 in 19 trusts)
Median 0.1% IQR (0-0.7%)
1 Not including day-cases
2 not including dermatology, endoscopy, ophthalmic paediatrics.
doi: 10.1371/journal.pone.0074219.t002
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completed (or partially completed) for all patients. In total, 63%
MRSA positive patients (458/760) and 50.5% of MRSA
negatives (481/951) were checklist positive (i.e. had at least
one risk factor documented). However, data on whether the
patient had a skin break or an in-situ device were commonly
missing. Among MRSA positives 237/760 (31%) and 234/760
(31%) were missing data on the presence of skin-breaks and/or
in-situ devices respectively. For MRSA negative admissions
the corresponding proportions were 343/951 (36%) and
315/951 (33%).
Mean sample turn-around time (the time between swabbing
and the result becoming available) was 2.87 (±1.33) days for
MRSA positive results and 1.75 (± 0.9) days for MRSA
negative results.
Individual patient management data showed that 78%
(596/760) of newly identified MRSA positive patients and 67%
(640/951) of the MRSA negative patients were admitted in the
same week that they were screened, the remainder having
been screened in pre-admission clinics. As shown in Table 5,
16% of the newly identified MRSA positive patients were pre-
emptively isolated on admission, 6% were pre-emptively
decolonised, and 37% were discharged before their screen
result was available. Once the result was known, 55% of those
newly identified positive patients who were still in-patients were
isolated. Similarly, a third (33%) of the admitted MRSA
negative patients were discharged before their screening result
was available.
Table 5. Patient management of admitted new MRSA
positives and MRSA negatives.
 MRSA +ves n= 596 MRSA –ves n= 640
Proportion isolated pre-
emptively on admission 16% (93/596) 6% (38/640)
Proportion decolonised
pre-emptively on
admission
6% (36/596) 9% (59/640)
Proportion discharged
before result available 37% (219/596) 33% (213/640)
Proportion of MRSA
positive admissions who
were still in-patients and
who were isolated after
result known
55%(205/3761) N/A
Proportion of MRSA
positive admissions who
were still in-patients and
who were decolonised
after result known
97% (363/376) N/A
1 data missing for one admission
doi: 10.1371/journal.pone.0074219.t005 The extra yield of MRSA positive patients using
universal admission screening compared to other
screening strategies
Table 6 compares the number of screens that would be
performed in an “average” trust each week using four different
screening strategies, and estimates the number of MRSA
positive patients that would be identified by each strategy.
Compared to universal screening of all admissions, checklist
activated screening would detect 80% of the MRSA positive
patients (equivalent to an average of two fewer MRSA patients
detected/week/trust) whilst halving the number of screens
(Table 6). Results were similar across each trust category.
Screening high-risk specialty admissions only would detect
less than 10% of MRSA positive patients whilst reducing
screening by nearly 90%, although the reduction in screening
would be less, 73% and 80% in specialist and teaching trusts
respectively, and the detection of MRSA would be higher at
24% and 16% respectively.
Combining screening of all admissions to high-risk
specialties with checklist activated screening for all other
admissions would yield similar results to using checklist
activated screening for all admissions. Again results were
similar across trust category, although the reduction in
screening would be lower (30%) in specialist trusts and
detection of MRSA would be slightly higher (89%) in acute
trusts.
Discussion
This study, with its high response rate (86%), provides a
more complete and representative picture of MRSA screening
practice in the current NHS in England than is available from
the literature on implementation, detection rates, potential yield
Table 6. The yield of MRSA achieved by universal
admission screening for the average NHS trust compared
to three other screening strategies.
 
Screen all
admissions
Checklist
activated
screening
(CLAS) all
admissions
Screen only
high-risk
specialty
admissions
Screen high-
risk specialty
admissions +
CLAS for low-
risk speciality
admissions
No. of screens
per week 790 398 87 448
Total no. MRSA
positives
identified
11.3 9.1 1.0 9.3
Percentage of
admissions
screened
100% 50% 11% 56%
Percentage of
MRSA positives
identified
100% 81% 8.5% 82%
doi: 10.1371/journal.pone.0074219.t006
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from different screening strategies and management of
patients.
There were three main findings. Firstly, implementation of
universal mandatory admission screening was poor for
emergency admissions (61%) and eligible day-case
admissions (47%), although better for electives (81%).
Secondly, the prevalence of MRSA colonisation on admission
was low at 1.5% (overall), 2.1% (emergency), 0.9% (electives)
and 0.7% (day -cases). Approximately half of these were
already known to be MRSA positive. The point prevalence of
MRSA amongst in-patients was 3.3%. Numbers needed to
screen in order to identify one new positive were, therefore,
high (ranging from 97 for emergency admissions in acute trusts
to 462 for day-case admissions in acute trusts). Thirdly,
checklist activated screening would detect 80% of the MRSA
positive patients detected by universal screening of all
admissions, whilst halving the number of laboratory screens.
Screening high-risk specialty admissions would detect only
10% of MRSA positive patients (more in teaching and specialist
trusts) whilst reducing screening by 90%.
Other important findings concern patient management, with
over three quarters of trusts reporting a policy of pre-emptive
isolation for patients with previous MRSA and nearly half
reporting a policy of pre-emptive isolation for admissions to
high-risk specialties. In practice, however, although most
patients with MRSA received decolonisation, isolation of
positive patients was limited. A third were discharged before
their screen result was available and nearly half of those with
newly identified MRSA who remained in hospital after the result
was known were not isolated, and nor were a third of those
with MRSA on the day of the in-patient point prevalence study.
An exception was specialist trusts where nearly all were
isolated due to the lower prevalence.
Comparison of our findings to those from outside the English
NHS system or Republic of Ireland is hampered by a lack of
comparable studies in the literature [22-27] because of large
differences in their settings and healthcare systems. This
includes the political imperative in the UK to reduce MRSA
infections, which led to legislation and a multitude of national
infection control interventions. Many of these preceded the
introduction of universal admission screening, during which
time MRSA rates fell considerably [3,7]. Comparison with some
of the studies outside the UK is also difficult because they
focussed on comparing PCR screening to more traditional
culture methods [22,23,26]. However, we found PCR to be little
used in England, which may due in part to a cluster
randomised controlled trial in the NHS that failed to show its
clinical benefit over chromogenic agar plating for universal
screening [14].
The major findings of this audit differed from the only
comparable multi-hospital study within the UK, the Scottish
Pathfinder study [28-31]. While both studies reported that
approximately half the admission prevalence was made up of
newly identified MRSA positives [28,29], implementation of
universal admission screening was lower in our study
compared to the Pathfinder, where 85% of emergency and
98% of elective admissions were screened. This may reflect
the fact that for Pathfinder, universal admission screening had
been implemented as part of a specific year-long (2008-9)
research study in 6 hospitals in three NHS “Boards” with a
team of research nurses following admissions and reminding
wards to screen if they had overlooked individual patients.
The overall admission prevalence of MRSA on admission
(1.5%) is lower than that reported in Pathfinder (2.4%) (20) and
a study in a single English hospital [12]. This may reflect a
temporal decline of MRSA bacteraemias in England [32] with a
38% decrease reported between April 2009 and June 2011
[32]. A parallel reduction in MRSA colonisation was reported in
the Pathfinder report (5.5% to 3.5% between 2008 and 2009)
and in acute care of the elderly wards in an Irish teaching
hospital (from 9% to 2% between 2007 and 2010 [15]).
The proportion of MRSA positive patients who would be
identified by checklist activated screening (81%) was the same
as that reported in Pathfinder [33] and in a study from an acute
English trust in 2007 [12], despite differences between
checklists. The proportions of admissions that would be
checklist positive and therefore require screening were also
similar (50% in this National One-Week (NOW) audit study and
57% in the Scottish Pathfinder and the acute English trust
studies) [12,33]. Pathfinder also examined use of a short three
item checklist (previous history of MRSA, presence of wounds
or indwelling devices, and admissions not from home). They
reported that this would detect 50% of MRSA positive patients
but require only 10% of admissions to be screened. When we
applied this checklist to our data we found it detected 68% of
MRSA positive patients but that 26% of all admissions would
require screening. When comparing the two studies it should
be noted that the Pathfinder study was much smaller than the
NOW study (6 hospitals admitting a total of 160,000 patients
between them in a year, compared to 144 hospitals admitting
over 80,000 emergency patients between them in a week) but
collected much more detailed individual level information.
Universal MRSA admission screening involves a lot of work
for a very low yield of new cases of MRSA carriage. In addition,
many of these cases will not be optimally managed as the
ability to isolate patients in the English NHS continues to be
limited [20] even though levels of MRSA are falling. Checklist
activated screening would seem to be an attractive option,
reducing the number of laboratory screens required by 50%
whilst still identifying 80% of MRSA positives. However, given
the relatively low compliance we report with a national
mandatory universal admission screening programme
(presumably the easiest screening policy to routinise and
implement), this should give pause for thought in respect of
how well any policy of checklist activated screening would be
implemented. NOW study infection control nurses used the
standard prevalence surveillance techniques of interrogation of
hospital databases, review of notes and examination or
interview of patients but were unable to find risk data on a
significant number of patients, which may be more reflective of
actual clinical practice. This indicates that accurate
implementation of a checklist by admitting nurses may not be a
feasible option and that audit of compliance with such a
strategy may prove difficult.
Screening all admissions to “high-risk” specialties, the
national strategy which preceded universal admission
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screening [2], gives a low yield of MRSA colonised patients, but
given the likely difficulties in implementing checklist activated
screening, this strategy may prove a more attractive and
feasible option as it would reduce the amount of screening to
10% of present levels but may identify the patients with the
highest potential excess morbidity, mortality and probable costs
due to MRSA infection. Indeed a recent model simulating
transmission in three hospitals in one region, based on Dutch
parameters, but considered from the USA perspective, found
that “high-risk” screening was more cost effective than
universal [22]. Cost effectiveness varied with admission
prevalence, as in a Swiss modelling study [23]. It remains
unclear what the most cost-effective screening strategy for
hospitals in England should be, until data from the NOW audit
is used to populate an extended version of an individual-based
transmission dynamic health economic model (30) to evaluate
the effectiveness and cost-effectiveness of different screening
strategies in different types of trust and MRSA prevalence
levels. This health economic evaluation is the subject of a
subsequent paper. Until the Department of Health has
reviewed all the evidence and policy implications, English
hospitals are recommended to continue to implement the
current policy & maximise use of isolation rooms.
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